Financials
Financial year 2025
Pharma & Finance Consulting from Beerse, company number BE0791674606, closed financial year 2025 with a result of € 6,378 after tax. For that financial year Pharma & Finance Consulting recorded a gross margin of € 14,707 and equity of € 33,385. Compared with financial year 2024, the result moved from € 9,330 to € 6,378. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 33,385
▲ 24% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 6,378
▼ 32% vs 2024
Profit after tax over the fiscal year.
€ 35,011
▲ 173% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 30,885.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 7,173
▼ 38% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 186
▼ 66% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 6,842
▼ 5% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 32,685 | € 18,773 | € 14,707 | ▼ 22% |
| Profit after taxes | € 18,093 | € 9,330 | € 6,378 | ▼ 32% |
| Equity | € 18,927 | € 27,007 | € 33,385 | ▲ 24% |
| Total debts | € 28,034 | € 16,920 | € 8,799 | ▼ 48% |
| Cash | € 23,938 | € 12,839 | € 35,011 | ▲ 173% |
| Retained profit | € 16,427 | € 24,507 | € 30,885 | ▲ 26% |
| Dividend | € 1,666 | € 1,250 | € 0 | ▼ 100% |
| Balance sheet total | € 46,961 | € 43,926 | € 42,184 | ▼ 4% |
Key figures of Pharma & Finance Consulting, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Pharma & Finance Consulting?
What happened at Pharma & Finance Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 6,378 (▼ 32% vs 2024). Source: NBB ↗
- New establishment in Beerse. KBO
- Start of the company according to the CBE. KBO
In short
From € 18,093 profit in 2023 to € 6,378 profit in 2025.
Paid € 15,661 in corporate taxes since 2023.
Best year ever: 2023, with € 18,093 profit.
Paid out € 2,916 in dividends to the owners in total.
Management
Behind Pharma & Finance Consulting is Tinne Braspenning. Tinne Braspenning is also behind Integrated Strategic Market Acces Services.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Pastoor Mensaertstraat 45
2340 Beerse
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0791.674.606
- VAT number
- BE 0791.674.606
- Registered office
- Pastoor Mensaertstraat 45, 2340 Beerse
- Names & denominations
- Pharma & Finance Consulting · P&F Consulting
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 September 2022
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige diensten op het gebied van informatietechnologie en computer
Ontwerpen van computerprogramma’s
Uitgeven van overige software
Overige zakelijke dienstverlening, neg
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computerconsultancy-activiteiten
+1